Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05869487
Recruiting Not applicable

Calf Circumference Versus X-ray Absorptiometry in the Diagnosis of Sarcopenia in Elderly Hospitalized Patients

NCT05869487 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Régional d'Orléans
Phase
Not applicable
Started
2023-12-11
Last updated
2025-12-30

Condition(s) studied

Sarcopenia

Investigational drug(s) / intervention(s)

Dual-energy X-ray absorptiometry

Dual-energy X-ray absorptiometry: Whole body x-ray absorptiometry

Study summary

This is a prospective single-center study to evaluate a diagnostic method. The main objective of the study is to evaluate the performance of calf circumference as a diagnostic method for sarcopenia in hospitalized elderly people, compared to a gold standard method which is X-ray absorptiometry. The study population are hospitalizing participants aged 75 years and older with an indication to search for sarcopenia.

Eligibility

Sex
ALL
Min age
75 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age greater than or equal to 75 years * Hospitalization in a medical department or in the follow-up care or rehabilitation department of the Hospital Center of Orléans * Presence of an etiological criterion of undernutrition * Presence of a decrease in muscle strength Exclusion Criteria: * Presence of one of two phenotypic criteria for undernutrition other than sarcopenia, which are body mass index less than 22 kilogram per square meter and weight loss (≥ 5 percent over 1 month or ≥ 10 percent over 6 months or ≥10 percent compared with usual weight before the disease). * Refusal to participate in the study * Patient under legal protection * Impossible to perform X-ray absorptiometry (behavioral problems, functional constraints to climb on the DXA machine) * Person not affiliated to a social security system

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU d'Orléans Orléans France Recruiting

More Centre Hospitalier Régional d'Orléans trials in France

Study of Tolerance to the Application of Cold Plasma in the Treatment of Chronic Wounds Recruiting
Effect of Inspiratory Muscle Training in Obstructive Sleep Apnea Syndrome. Recruiting
Ultrasound Evaluation of Cardiac Function During Spontaneous Breathing Trials Recruiting
Effect of the "Sitting Out of Bed in an Arm-chair Position" in ICU on Functional Recovery Among Ventilated Patients Recruiting
Benefits of Judicial Assistance Dogs for Child Victims in Child Advocacy and Pediatric Assessment Units (UAPEDs) Starting soon

Other trials for the same condition

Physical Activity Oxidative Stress and Inflammation With Ageing Starting soon
Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact Recruiting
Health Data from Well on My Legs Program Active, not recruiting
JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients Recruiting
Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05869487 on ClinicalTrials.gov ↗ ← All trials in France